The Prognositic Value Of Serum CEA Or CYFRA21-1Level For The Non-small-cell Cancer Patients Undergone Adjuvant Chemotherapy

Objective:The aim of this study was to test whether CEA or cyfra21-1is a predictive factor for prognosis after adjuvant chemotherapy in non-small-cell lung cancer patients.Method:This study was a retrospective study.169non-small lung cancer was collected in our hospital, who have undergone complete resection and2-cycles adjuvant chemotherapy.All cases were selected at the same time meet the following requirements:1. complete resection(2005The International Committee of Lung Cancer Staging);2. All cases were confirmed by abdominal CT, brain CT or MRI, bone ECT and other tests to exclude distant metastasis;3. All cases’stage were Ib～Ⅲa (pTNM);4. All cases received adjuvant chemotherapy within2months after operations and the cycles of adjuvant chemotherapy≥2. The exclusion criteria of cases:1. Malignancy history.including lung cancer;2. Neoadjuvant chemotherapy or radiotherapy before sugery;3. Radiotherapy after surgery. The medicine was Platinum combined with Gemcitabine/Paclitaxel/Vinorelbine. The dose of the drugs: GP (Gemcitabine1000～1250mg/m2, dl, d8; cis-platin75mg/m2, dl or carboplatin AUC=5, d1. TP paclitaxel175～200mg/m2, dl; cis-platin75mg/m2, dlor carboplatin AUC=5, d1. NP Vinorelbine25mg/m2, d1, d8; carboplatin80mg/m2, d1. The chemotherapy cycles were at least2. The medicine was Platinum combined with Gemcitabine/Paclitaxel/Vinorelbine. The dose of the drugs:GP (Gemcitabine1000～1250mg/m2, d1, d8; cis-platin75mg/m2, d1or carboplatin AUC=5, dl. TP paclitaxel175-200mg/m2, dl; cis-platin75mg/m2, dlor carboplatin AUC=5, dl. NP Vinorelbine25mg/m2, dl, d8; carboplatin80mg/m2, d1. The chemotherapy cycles were at least2.Result:The high level of CEA, CYFRA21-1after2cycles adjuvant chemotherapy were poor prognostic factor for OS,the risk-ratio(RR) was2.003,1.702respectively. The high CEA level was a poor prognostic factor(RR1.152) for the DFS. The median survival time(MST) of high CEA level group was26months, normal group61months, P<0.0001. The median DFS time of the high CEA group and normal group was34,53months respectively, P<0.0001. The MST of high CYFRA21-1group vs normal group was43vs56months, P<0.0001.Conclution:The high level of serum CEA or CYFRA21-1after two cycles adjuvant chemotherapy is a poor prognostic factor for non-small-cell lung cancer.